| Identification | Back Directory | [Name]
6-Bromo-4-[1-[[6-[(4,4-dimethyl-1-piperidinyl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-1H-1,2,3-triazol-4-yl]-1H-indazole | [CAS]
2499664-52-5 | [Synonyms]
6-Bromo-4-[1-[[6-[(4,4-dimethyl-1-piperidinyl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-1H-1,2,3-triazol-4-yl]-1H-indazole
6-Bromo-4-(1-((6-((4,4-dimethylpiperidin-1-yl)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)-1H-indazole | [Molecular Formula]
C25H27BrN8 | [MOL File]
2499664-52-5.mol | [Molecular Weight]
519.44 |
| Chemical Properties | Back Directory | [density ]
1.54±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
11.05±0.40(Predicted) | [color ]
Light yellow to brown |
| Hazard Information | Back Directory | [Uses]
STM3006 is a highly potent, selective, and orally active inhibitor of METTL3 (IC50: 5 nM). STM3006 can reduce the m6A level, promote the formation of dsRNA, trigger a cell-intrinsic interferon response, and enhance the killing effect of T cells on tumors. STM3006 has anti-tumor activity, and its combination with anti-PD-1 immunotherapy yields better results[1][2]. | [References]
[1] Andrew A Guirguis, et al. Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity.Cancer Discov. 2023 Oct 5;13(10):2228-2247. DOI:10.1158/2159-8290.CD-23-0007
[2] Brichkina A, et al. Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy. Signal Transduct Target Ther. 2023 Dec 11;8(1):448. DOI:10.1038/s41392-023-01696-x |
|
| Company Name: |
nanjing
|
| Tel: |
13376082704 13376082704 |
| Website: |
www.linye-e.com/ |
|